BR112014002377A2 - agente intensificador da função diastólica do ventrículo esquerdo - Google Patents

agente intensificador da função diastólica do ventrículo esquerdo

Info

Publication number
BR112014002377A2
BR112014002377A2 BR112014002377A BR112014002377A BR112014002377A2 BR 112014002377 A2 BR112014002377 A2 BR 112014002377A2 BR 112014002377 A BR112014002377 A BR 112014002377A BR 112014002377 A BR112014002377 A BR 112014002377A BR 112014002377 A2 BR112014002377 A2 BR 112014002377A2
Authority
BR
Brazil
Prior art keywords
left ventricular
diastolic
diastolic function
ventricular diastolic
agent
Prior art date
Application number
BR112014002377A
Other languages
English (en)
Inventor
Fuchibe Kazuhiro
Takahashi Masaya
Kanaji Toshiya
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR112014002377A2 publication Critical patent/BR112014002377A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “agente intensificador da função diastólica do ventrículo esquerdo” a presente invenção se refere a um agente para o tratamento da insuficiên-cia cardíaca, que melhora a função diastólica do ventrículo esquerdo sem depender de um efeito diurético ou efeito vasodilatador; controla a condição patológica da in-suficiência funcional diastólica; e impede a recorrência, e capaz de prevenir a dis-pneia e morte decorrentes da condição patológica. por agir diretamente sobre o coração, o ácido 4-[(2-{(2r)-2-[(1e,3s)-4-(4-fluorofenil)-3-hidroxi-1-buten-1-il]-5-oxo-1-pirrolidinil}etil)tio] butanóico melhora a função diastólica do ventrículo esquerdo, e pode tratar eficazmente a insuficiência funcional diastólica entre os tipos de insuficiência cardíaca. consequentemente, a presente invenção pode fornecer um novo agente para o tratamento da insuficiência cardíaca capaz de aliviar a insuficiência funcional diastólica, sendo que, para este fim, nenhum eficaz terapêutico método foi estabelecido.
BR112014002377A 2011-08-02 2012-08-01 agente intensificador da função diastólica do ventrículo esquerdo BR112014002377A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011169389 2011-08-02
PCT/JP2012/069609 WO2013018837A1 (ja) 2011-08-02 2012-08-01 左室拡張機能改善剤

Publications (1)

Publication Number Publication Date
BR112014002377A2 true BR112014002377A2 (pt) 2017-02-21

Family

ID=47629356

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002377A BR112014002377A2 (pt) 2011-08-02 2012-08-01 agente intensificador da função diastólica do ventrículo esquerdo

Country Status (16)

Country Link
US (1) US9682065B2 (pt)
EP (1) EP2740475A4 (pt)
JP (1) JP6052175B2 (pt)
KR (1) KR20140056250A (pt)
CN (1) CN103717219B (pt)
AU (1) AU2012290987B2 (pt)
BR (1) BR112014002377A2 (pt)
CA (1) CA2842906A1 (pt)
HK (1) HK1197194A1 (pt)
IL (1) IL230686A0 (pt)
MX (1) MX2014000971A (pt)
RU (1) RU2627842C2 (pt)
SG (1) SG2014007603A (pt)
TW (1) TW201321003A (pt)
WO (1) WO2013018837A1 (pt)
ZA (1) ZA201401487B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612921T3 (es) 2012-07-19 2017-05-19 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
ES2635635T3 (es) 2013-03-15 2017-10-04 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
CA2910398A1 (en) 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
PL3411047T3 (pl) * 2016-02-04 2021-11-15 Czap Research And Development, Llc Nośniki kompleksów inkluzyjnych cyklodekstryn o kontrolowanym uwalnianiu i stratyfikowane
WO2018216640A1 (ja) 2017-05-22 2018-11-29 小野薬品工業株式会社 Ｅｐ４アンタゴニスト
RU2762989C1 (ru) * 2020-09-28 2021-12-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ лечения собак, больных дилатационной кардиомиопатией, осложненной застойной сердечной недостаточностью

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (pt) 1970-06-10 1975-02-04
JPS5231404B1 (pt) 1971-04-28 1977-08-15
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US5938890A (en) 1998-06-27 1999-08-17 Automatic Manufacturing Systems, Inc. Adhesive components peel and apply apparatus and method
MXPA02006322A (es) 1999-12-22 2002-12-13 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
EP1132086B1 (en) * 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
CA2420042A1 (en) 2000-08-22 2003-02-18 Mikio Ogawa Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
AU2002328338C1 (en) 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
DE60208568T2 (de) 2001-07-16 2006-10-05 F. Hoffmann-La Roche Ag Prostaglandinanaloga als ep4-rezeptoragonisten
TWI313608B (en) * 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
US20080234337A1 (en) 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
EP1782830A4 (en) * 2004-08-10 2009-07-29 Ono Pharmaceutical Co PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST
JP2006321737A (ja) 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤

Also Published As

Publication number Publication date
CA2842906A1 (en) 2013-02-07
RU2627842C2 (ru) 2017-08-14
TWI562778B (pt) 2016-12-21
US20140179606A1 (en) 2014-06-26
AU2012290987B2 (en) 2017-04-20
US9682065B2 (en) 2017-06-20
AU2012290987A1 (en) 2014-02-20
EP2740475A4 (en) 2015-02-25
HK1197194A1 (en) 2015-01-09
ZA201401487B (en) 2015-12-23
JP6052175B2 (ja) 2016-12-27
JPWO2013018837A1 (ja) 2015-03-05
CN103717219A (zh) 2014-04-09
SG2014007603A (en) 2014-03-28
NZ620451A (en) 2015-11-27
MX2014000971A (es) 2014-02-27
WO2013018837A1 (ja) 2013-02-07
RU2014107904A (ru) 2015-09-10
IL230686A0 (en) 2014-03-31
CN103717219B (zh) 2017-02-15
EP2740475A1 (en) 2014-06-11
TW201321003A (zh) 2013-06-01
KR20140056250A (ko) 2014-05-09

Similar Documents

Publication Publication Date Title
BR112014002377A2 (pt) agente intensificador da função diastólica do ventrículo esquerdo
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
BR112012010786A2 (pt) udo de derivados de benzo-heterociclo para medir e tratar câncer ou para inibir metástase de câncer
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
BR112015031864A2 (pt) compostos de pirimidinadiona contra as condições cardíacas
JP2014515038A5 (pt)
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
BR112014010228A8 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
CR20120448A (es) Compuesto heterocíclico
BR112012014990A2 (pt) composto, método para tratar uma doença ou condição dependente de calicreína de plasma, e, composição.
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112014028042A2 (pt) inibidores de nampt
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
BR112015022385A2 (pt) droga para uma doença respiratória
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112022006572A2 (pt) Inibidores orais do fator d do complemento
BR112015022762A2 (pt) composto éster de ácido guanidino benzóico
BR112018077392A2 (pt) composição farmacêutica e derivado de piranocromenil fenol oticamente ativo compreendendo a mesma
BR112017028224A2 (pt) composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
BR112017014016A2 (pt) método de redução da pressão intraocular, e, composição farmacêutica.
BR112013008034A2 (pt) método para normalizar hemeostase comprometida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2525 DE 28-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.